

Patient Name	
Date of CASGEVY infusion	
CASGEVY Patient ID number	

CASGEVY Treating Physician Name	
CASGEVY Treating Physician Contact Information	
CASGEVY Treating Physician Contact Information After Hours	

CASGEVY word mark and design are registered trademarks of Vertex Pharmaceuticals Incorporated
 Additional copies of this Patient Card are available upon request.
 Approved by the Saudi Food and Drug Authority May 2024



Important safety information regarding CASGEVY®▼ (exagamglogene autotemcel)

Patient Card

Carry this card with you at all times (duplicates or pictures kept on your smart device are recommended). Show it to any doctor who sees you and when you go to any hospital or healthcare clinic.

Tell any healthcare provider who sees you that you have been treated with CASGEVY (exagamglogene autotemcel).

As you have been treated with CASGEVY, you should never donate blood, organs, tissues or cells.

You can report side effects directly to the National Pharmacovigilance Centre (NPC):
 Saudi Food and Drug Authority Call Center: 19999
 E-mail: npc.drug@sFDA.gov.sa
 Website: <https://ade.sFDA.gov.sa/>



Version 1.0
 Date of Preparation: May 2024
 Approved by the Saudi Food and Drug Authority May 2024



■ Information on Side Effects

Make sure you have all your blood tests as ordered by your doctor.

Call your doctor or nurse right away if you experience any symptoms of bleeding:

- Severe headache
- Abnormal bruising
- Prolonged bleeding
- Bleeding without injury such as:
 - ◆ Nosebleeds
 - ◆ Bleeding from gums
 - ◆ Blood in your urine, stool or vomit
 - ◆ Coughing up blood

■ Healthcare Provider Information

- This patient has received CASGEVY (exagamglogene autotemcel) infusion. The infusion was preceded by the administration of a fully myeloablative conditioning agent.
- **The patient is at risk of bleeding due to the possibility of a prolonged period of thrombocytopenia prior to platelet engraftment.**
- Please contact the patient's treating physician listed on the back of this card for further information.
- For more information, refer to the CASGEVY Summary of Product Characteristics.
- Report any suspected adverse reactions due to CASGEVY (see reporting information on the front page).
- Any suspected adverse reactions to CASGEVY should also be reported to Vertex Pharmaceuticals on 800-844-3907 or at reportAE@vrtx.com.